medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Title: Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm Development and Rupture: Insights from Genetic and Experimental Models

Author: Yaozhong Liu[1], Huilun Wang[1,2], Minzhi Yu[3], Lei Cai[4], Ying Zhao[1], Yalun Cheng[1], Yongjie Deng[1], Yang Zhao[1], Haocheng Lu[5], Xiaokang Wu[1], Guizhen Zhao[1,6], Chao Xue[1,7], Hongyu Liu[1], Ida Surakka[1], Anna Schwendeman[3], Hong S. Lu[4], Alan Daugherty[4], Lin Chang[1], Jifeng Zhang[1], Ryan E. Temel[4,*], Y. Eugene Chen[1,8,*], Yanhong Guo[1,*]

[1]Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan Medical Center, Ann Arbor, Michigan, USA.

[2]Department of Molecular Physiology and Biological Physics, University of Virginia School of Medicine, Charlottesville, Virginia, USA.

[3]Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, USA.

[4]Saha Cardiovascular Research Center and Department of Physiology, College of Medicine, University of Kentucky, Lexington, Kentucky 40536.

[5]Department of Pharmacology, Southern University of Science and Technology, Guangdong, China.

[6]College of Pharmacy Health, University of Houston, Houston, Texas, USA.

[7]Department of Internal Medicine, Rochester General Hospital, Rochester, New York, USA.

[8]Center for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, Ann Arbor, Michigan, USA.

Total word count: 8255

*** To whom correspondence should be addressed:**

Yanhong Guo, M.D., Ph.D., Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109, Phone: 734-764-1405, Email: yanhongg@umich.edu

Or

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Y. Eugene Chen, M.D., Ph.D., Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109, USA. Phone: 734-936-9548, Email: echenum@umich.edu

Or

Ryan E. Temel, Ph.D., Saha Cardiovascular Research Center and Department of Physiology, College of Medicine, University of Kentucky, Lexington, KY 40536, USA. Phone: 859-218-1706, Email: ryan.temel@uky.edu

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Abstract:

Abdominal aortic aneurysm (AAA) is a life-threatening vascular disease without effective medications. This study integrated genetic, proteomic, and metabolomic data to identify causation between increased triglyceride (TG)-rich lipoproteins and AAA risk. Three hypertriglyceridemia mouse models were employed to test the hypothesis that increased plasma TG concentrations accelerate AAA development and rupture. In the angiotensin II-infusion AAA model, most *Lpl*-deficient mice with severely high plasma TG concentrations died of aortic rupture. Consistently, *Apoa5*-deficient mice with moderately increased TG concentrations had accelerated AAA development, while human *APOC3* transgenic mice with dramatically increased TG concentrations exhibited aortic dissection and rupture. Increased TG concentrations and palmitate inhibited lysyl oxidase maturation. Administration of antisense oligonucleotide targeting *Angptl3* profoundly inhibited AAA progression in human *APOC3* transgenic mice and *Apoe*-deficient mice. These results indicate that hypertriglyceridemia is a key contributor to AAA pathogenesis, highlighting the importance of triglyceride-rich lipoprotein management in treating AAA.

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Introduction

Abdominal aortic aneurysm (AAA) is a progressive vascular disease characterized by the localized enlargement of the abdominal aorta. The prevalence of AAA is estimated to be as high as 8% in men and 2% in women over 65 years of age.[1] Most AAAs are asymptomatic, but the mortality rate is up to 80% if rupture occurs.[2] As maximum aortic diameter is the most established predictor of aneurysm rupture, current guidelines recommend considering surgical repair for asymptomatic AAA patients when maximal aortic diameter is ≥ 50 mm in women and ≥ 55 mm in men. Open surgical or percutaneous endovascular aneurysm repair is still the only therapeutic option.[3] Patients with AAA smaller than these thresholds are typically monitored through imaging surveillance. AAA-relevant risk factors, including smoking, male sex, aging, hypertension, and hyperlipidemia, are associated with enhanced aneurysm formation and growth. Currently, medications to reduce AAA risk factors, such as angiotensin II (AngII) receptor antagonists, beta-adrenoceptor blockers, statins, and anticoagulants, have not been proven effective in halting the growth of an aneurysm or preventing the rupture of asymptomatic AAA based on the findings from randomized controlled trials.[4,5]

Our recent comprehensive genome-wide association studies (GWAS) meta-analysis, which included approximately 40,000 individuals with AAAs and over 1 million individuals without AAAs, has demonstrated that one-third of the lead variants at the 121 genome-wide significant AAA risk loci are associated with major lipid fractions, such as total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), or high-density lipoprotein cholesterol (HDL-C).[6] Other genetic association studies have identified that a 1-standard deviation increase in TG concentrations is associated with a 69% higher risk of AAA.[7,8] Population-based studies have reported that individuals with increased serum very low-density lipoprotein-cholesterol (VLDL-C) and TG concentrations are more likely to develop larger AAA sizes and have a higher risk of rupture.[9,10] These epidemiologic and genetic findings suggest that increased TG-rich lipoproteins (TRL) may accelerate AAA development and rupture, and modulating TG concentrations or metabolites may become new therapeutic strategies for AAA.

TG, also known as triacylglycerols (TAG), are composed of glycerol and fatty acids and are the most abundant lipids in the body. Chylomicrons transport dietary triglycerides from the small intestines, and VLDLs transport endogenously synthesized triglycerides from the liver to peripheral tissues, such as the heart, skeletal muscle, and adipose tissues. Triglyceride metabolism is a complex process involving the breakdown and utilization of this lipid. Several proteins and enzymes play critical roles in regulating triglyceride metabolism.[11] Among these, lipoprotein lipase (LPL), ApoC-III

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(apolipoprotein C-III, APOC3), ApoC-II, ApoA-V (apolipoprotein A5, APOA5), and angiopoietin-like proteins (ANGPTL3, ANGPTL4, and ANGPTL8) are key players. LPL is a critical enzyme that facilitates the hydrolysis of triglycerides carried by chylomicrons and VLDL into free fatty acids (FFA) and glycerol, allowing them to be utilized by various cells for energy or storage. Our previous study found that an intronic LPL variant, associated with increased LPL expression, was strongly related to reduced plasma TG concentrations and AAA risk.[6] APOA5 is almost exclusively expressed in the liver and secreted in conjunction with VLDL particles. ApoC-III is a constituent of chylomicrons and VLDL particles and inhibits LPL activity, while ApoA-V and ApoC-II enhance LPL activity and promote the clearance of TG-rich lipoproteins. ANGPTL3 and ANGPTL8 are secreted proteins and inhibitors of LPL-mediated plasma TG clearance. In numerous studies involving humans and animals, loss-of-function of APOC2 or APOA5 is associated with increased plasma concentrations of TG and chylomicronemia.[12,13] Among the putatively causal circulating proteins associated with AAA, we observed that higher APOA5 expression is associated with decreased AAA risk.[6] Conversely, gene silencing of APOC3 or ANGPTL3 significantly reduced TG and TC concentrations, making this method an effective strategy for lowering plasma lipids and preventing cardiovascular diseases.[14-17] In the present study, we demonstrated that increased TG-rich lipoproteins accelerate AAA formation and rupture, and we provide evidence that effective management of plasma TG concentrations can alleviate AAA progression.

Methods

A detailed description of the methods is available in the Supplemental Materials. All animal procedures followed the protocols approved by the Institutional Animal Care & Use Committee (IACUC) at the University of Michigan and University of Kentucky.

Statistic analysis

Analyses of RNA sequencing and genetic data were performed using R language (v4.3.0). Statistical analyses of other data were conducted using GraphPad Prism 10. Most of the data are presented as mean ± standard error of the mean (SEM). The distribution of data was assessed using the Kolmogorov-Smirnov test (for $n > 4$) or the Shapiro-Wilk test (for $n \leqslant 4$). For normally distributed data, Student's t-tests were used to compare two groups, one-way analysis of variance (ANOVA) was used to compare multiple groups, and the Sidak method was applied for multiple comparison correction. For non-normally distributed data, Mann-Whitney U tests were used to compare two groups, Kruskal-Wallis tests were employed to compare multiple groups, and the Dunn method was used for multiple comparisons correction. A P-value less than 0.05 was considered statistically significant.

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Results

Genetic, proteomic, and metabolic studies underscore high triglyceride-rich lipoproteins as a causal risk factor for AAA.

Genetic variants that modulate the expression of genes encoding the candidate proteins or the abundances of metabolites represent valuable tools for guiding therapeutic strategies. Recent studies have identified cis-acting protein quantitative trait loci (cis-pQTL) that can be used as instrumental variables (IVs) for inferring causality.[18,19] Combining cis-pQTL and GWAS findings, we performed Mendelian randomization (MR) analyses to assess the causal effects of circulating proteins on AAA risk and identified that 41 out of 2,698 circulating proteins were significantly associated with AAA after adjusting for multiple tests (Fig 1, full MR results in Supplementary Table 1). Among them, genetically determined circulating APOC3 (OR=1.84) and APOA5 (OR=0.61) had the most significant effects on AAA risk. Seven of the 41 circulating proteins, including APOC3, APOA5, LPL, APOE, PLTP (phospholipid transfer protein), PCSK9 (proprotein convertase subtilisin/kexin type 9), and LPA (lipoprotein(A)), play an important role in lipid metabolism, especially in VLDL and chylomicron metabolism (Fig 1B). Our previous GWAS findings demonstrated that 42 lead variants at the AAA risk loci are associated with major lipid fractions.[6] After prioritizing the role of five major lipoprotein components (HDL-C, LDL-C, TG, APOA1, and APOB) as risk factors for AAA, TG was the top-ranked risk factor for AAA with a marginal inclusion probability of 0.81 (P=0.007; Supplementary Table 2). Consistent with previous studies,[6-8] LDL-C, HDL-C, and APOA1 were significant factors (Supplementary Table 2). These genetic and proteomic findings indicate that TG-related metabolism may play a substantial role in AAA pathogenesis.

To further identify genetic associations between AAA risk loci and circulating metabolic traits, we utilized the data from a recently published GWAS study of 233 circulating metabolites to perform a two-sample MR analysis.[20] The NMR-measured metabolites included 213 lipid traits (lipids, lipoproteins, and fatty acids) and 20 non-lipid traits (amino acids, ketone bodies, and glucose/glycolysis-related metabolites).[20] Lipoproteins are classified by particle sizes (XXL, XL, L, M, S, and XS) and then subgrouped by the components (particle number, phospholipids, cholesterol, cholesterol ester, free cholesterol, and TG). For each metabolite, we used the inverse variance-weighted (IVW) method as the primary MR approach and MR-Egger analysis and weighted median-based regression methods as sensitivity analyses. We demonstrated that TG-rich lipoproteins, including VLDL, IDL (intermediate density lipoprotein), and LDL, and all the components in TRL particles, were positively associated with AAA risk, while HDL and glucose were negatively associated with AAA risk, consistent with population findings (Fig 1C, full MR results in Supplementary Table 3).[9,10,21,22] Interestingly, we

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

noticed that TG component of HDL was positively associated with AAA risk compared to other components in HDL particles, such as cholesterol and phospholipids (Fig 1C). Concomitantly, we observed that total fatty acid and saturated fatty acid, the metabolites of triglycerides, were also positively associated with AAA risk. These findings raise the possibility that lowering triglycerides and related metabolites could provide a therapeutic pathway for reducing the risk of AAA.

Impaired LPL activity accelerates AAA development and rupture.

Chronic subcutaneous infusion of AngII serves as a well-established AAA model in mice under hypercholesterolemic conditions, which includes using mice with deficiencies in apolipoprotein E (*Apoe*) or LDL receptor (*Ldlr*) or manipulating by adeno-associated virus-mediated overexpression of *Pcsk9* to induce hyperlipidemia.[23-25] Our previous GWAS demonstrated that LPL variants that lead to increased plasma TG concentrations were linked to an increased risk of AAA.[6] The MR analysis also identified circulating LPL levels to be negatively associated with AAA risk (Fig 1B). To validate whether increased TG concentrations caused by impaired LPL activity can result in AAA development and rupture, we infused AngII into male, inducible *Lpl*-deficient (i*Lpl*$^{-/-}$) mice fed a low-cholesterol Western diet. With AngII infusion, an aortic rupture occurred in 94% (16/17, combined data from two cohorts of animal studies) of i*Lpl*$^{-/-}$ mice compared to 9.5% (2/21, combined data from two cohorts of animal studies) aortic rupture rate in littermate control mice (Fig 2A-C, Supplementary Fig 1). The only survival i*Lpl*$^{-/-}$ mouse did not have AAA and had a plasma TG concentration of 474 mg/dL and TC concentration of 233 mg/dL. In contrast, after 1 week of Western diet feeding but before AngII infusion, the majority of the i*Lpl*$^{-/-}$ mice had severely increased TG concentrations, which were as high as 11,103 mg/dL (4,077 ± 3,218 mg/dL) compared to 66 ± 28 mg/dL in *Lpl*$^{f/f}$ mice (Supplementary Fig 1A). Saline infusion, as a control, did not cause aortic rupture in either genotype (Supplementary Fig 1C). These findings showed that severely increased TG concentrations as a consequence of LPL deficiency resulted in aortic rupture and death in the AngII-induced AAA model.

Then, we employed other mouse strains with increased, but not severely elevated, TG concentrations to validate our hypothesis. We performed all the following AAA studies in mice fed a standard rodent laboratory diet to minimize the effects of hypercholesterolemia induced by a Western diet. ApoA-V is produced in the liver and secreted into circulation, where it exerts an important role in regulating plasma TG concentrations by enhancing LPL activity to hydrolyze triglycerides. Male *Apoa5*-deficient mice showed a 2-3-fold increase in TG concentrations but no difference in TC concentrations (Fig 2D-G), consistent with previous findings.[12] AAA was evaluated after a 4-week AngII infusion. The hypertriglyceridemic *Apoa5*-deficient mice had increased

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

AAA incidence and larger maximal abdominal aorta diameter (Fig 2E, H, I). There was no difference in blood pressure before and after AngII infusion between *Apoa5*-deficient mice and their littermate controls (Fig 2J). This phenotype was not observed in *Apoa5*-deficient female mice, which had only slightly increased TG concentrations (Fig 2K-O). In addition, female mice demonstrate markedly lower incidences of AAA than males due to sex hormones or sex chromosomes.[26] These findings imply the causative roles of elevated TG concentrations in AAA pathogenesis.

Moderately to severely increased triglyceride levels accelerate AAA development and rupture in human *APOC3* transgenic mice.

Increased plasma ApoC-III concentrations are linked to enhanced production and slowed clearance of triglyceride-rich lipoproteins, causing hypertriglyceridemia. Human *APOC3* transgenic (h*APOC3* Tg) mice and age/sex-matched wild-type littermates were fed a standard rodent laboratory diet (Fig 3A). Compared with controls, male h*APOC3* Tg mice had about 7-fold increase in plasma TG concentrations (Fig 3B) and about 1-fold elevations in plasma TC concentrations (Fig 3C) and non-esterified fatty acids (NEFA, Fig 3D). We observed a low incidence of AAA in wild-type littermates (2 out of 17), similar to the literature.[26] However, there was a dramatically increased AAA incidence and a larger maximal diameter of the suprarenal aorta in h*APOC3* Tg mice (11 out of 13 surviving animals), as well as a higher dissection rate (8 out of 13 surviving animals) and another 2 mice dying from AAA rupture (Fig 3E-H). There was no difference in systolic blood pressure (SBP) between h*APOC3* Tg mice and controls (Fig 3I). A similar phenotype was observed in female mice (Fig 3J-O), indicating that dramatically increased TG concentrations accelerated AAA development, surpassing the protective effects of female hormones.

The effects of increased TG concentrations on AAA development were also evaluated in a PPE (porcine pancreatic elastase)-induced AAA model, in which AAA progression is independent of hypercholesterolemia.[27] Based upon a 50% increase in the maximal abdominal aorta diameter as AAA on day 14 post-operative, the incidence of AAA was 100% for both male and female h*APOC3* Tg and littermate control mice (Supplementary Fig 2 and Supplementary Fig 3). Male h*APOC3* Tg mice showed significantly larger maximal aortic diameters than littermate controls, demonstrating that increased TG concentrations accelerated AAA growth (Supplementary Fig 2A-E). Even though female h*APOC3* Tg mice had lower TG concentrations than males (635 ± 36 mg/dL v.s. 946 ± 258 mg/dL, $p = 0.0005$), the increased TG concentrations in females were sufficient to cause larger aortic diameters (Supplementary Fig 3A-D).

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

These findings from the three hyperglyceridemia mouse models indicate that increased TG concentrations accelerate AAA rupture and aneurysm growth.

Palmitate and increased triglyceride concentrations inhibit lysyl oxidase maturation in human aortic smooth muscle cells and aortas.

The pathophysiology of AAA is intricately linked to the disruption of smooth muscle cell (SMC) homeostasis within the aortic wall, including phenotypic switching, cell death, extracellular matrix (ECM) remodeling, and inflammatory responses.[28] Serum from *Apoa5*-deficient or h*APOC3* Tg mice, as well as VLDL and HDL particles, did not affect primary human aortic smooth muscle cell (HASMC) viability (Supplementary Fig 4A-C), while incubation with LDL slightly increased cell numbers (Supplementary Fig 4C). The presence of APOA5 in the conditional medium did not regulate the expression of contractile markers in the presence of either Platelet-Derived Growth Factor-BB (PDGF-BB) or Transforming growth factor-beta (TGFβ) (data not shown), suggesting other mechanisms may exist. APOC3 overexpression caused elevated plasma TG concentrations accompanied by increased plasma NEFA concentrations (Fig 3D and Supplementary Fig 2C). Palmitic acid (PA) is the most common saturated fatty acid in the human body, typically accounting for 20–30% of the total fatty acids.[29] Bulk RNA sequencing (RNA-seq) analysis was performed to compare PA-incubated HASMC with BSA-treated (vehicle control) cells. Compared to the BSA-incubated group, PA-incubated HASMC showed an apparent reduction in ECM assembly pathways, including collagen chain trimerization, elastic fiber formation and maturation, (Fig 4A-D), and increased expression of the inflammation-related gene (Supplementary Fig 5A-B, Supplementary Table 4).

TGF-β and lysyl oxidase (LOX) are crucial in regulating the cross-linking of collagen and elastin in the ECM. LOX was unexpectedly upregulated compared to the most downregulated genes in the elastic fiber formation and maturation pathways (Fig 4D). In primary HASMC, PA incubation induced the transcription of LOX, showing increased mRNA abundance by qRT-PCR (Fig 4E). LOX is initially synthesized as a preproprotein, which undergoes several post-translational modifications for its maturation and functional activation. Impairments in LOX activity, whether due to genetic mutations or LOX inhibitors, can lead to AAA formation and rupture.[30-32] Our RNA-seq data indicated that PA incubation downregulated the expression of BMP-1 (Bone morphogenetic protein 1), ADAMTS2 (a disintegrin and metalloproteinase with thrombospondin motif 2), and ADAMTS14, which are critical enzymes controlling LOX activation by the proteolytic removal of the propeptide region. We further confirmed that PA incubation downregulated BMP-1 and ADAMTS2 transcriptions in HASMCs (Fig 4F). Immunoblot analyses demonstrated that incubation with TGF-β increased the abundance of the

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

mature form of LOX. However, the presence of PA blocked its effect, resulting in a less mature LOX (Fig 4G, I). LOX overexpression increased the mature form of LOX in HASMC, which was suppressed by incubation with PA (Fig 4H), indicating that PA interferes with the maturation process of LOX in HASMC. Nicotine, one of the well-established AAA risk factors, also repressed LOX maturation in HASMC (Supplementary Fig 6). These findings suggest that PA and nicotine may play a synergistic role in the pathogenesis of AAA by blocking LOX activation.

To investigate the effects of increased circulating palmitate concentrations on the maturation of LOX in aortas, we administered ethyl palmitate, which can be hydrolyzed to free palmitate in rodents.[33] The mature LOX abundance in suprarenal abdominal aortas was inhibited significantly after administration of ethyl palmitate compared to the vehicle or control intact aortas (Fig 4J). Then, we examined whether increased TG concentrations affected the maturation of LOX in the aortas of h*APOC3* Tg and littermate control mice. There was no difference in the abundance of matured LOX in suprarenal abdominal aortas between the two groups without AngII infusion (Fig 4K). We observed a dramatic upregulation of mature LOX upon AngII infusion in control mice (Fig 4K), suggesting a protective and compensatory mechanism to enhance elastic fiber assembly to protect against the effects of AngII. However, this response disappeared in h*APOC3* Tg mice (Fig 4K), indicating that increased TG and/or palmitate inhibited LOX maturation in the aortas, which may contribute to AAA development and rupture.

Angptl3 ASO inhibits AAA formation and rupture in _APOC3_ Tg mice.

Based on the above findings, we asked whether lowering TG levels could attenuate AAA formation and rupture. We administrated fenofibrate and niacin, commonly used for treating hypertriglyceridemia, but only observed a 14-17 % reduction of plasma TG concentrations in h*APOC3* Tg mice (Supplementary Fig 7). N-acetylgalactosamine (GalNAc)-conjugated antisense nucleotides (ASO) targeting of hepatocyte ANGPTL3 results in significantly decreased plasma TG concentrations in animals and humans.[15,16,34] In h*APOC3* Tg mice, administration of *Angptl3* ASO dramatically suppressed hepatic *Angptl3* mRNA abundance by 64% and the plasma ANGPTL3 concentrations by 81% (Fig 5A-C). Consequently, administration of the *Angptl3* ASO significantly reduced concentrations of NEFA, triglycerides (from 1,119 ± 98 mg/dL to 586 ± 114 mg/dL) and total cholesterol (from 283 ± 103 mg/dL to 117 ± 58 mg/dL) (Fig 5D-F). Consistent with the above findings, increased TG concentrations in h*APOC3* Tg mice accelerated AAA development during AngII infusion (Fig 5G-L). After administration of *Angptl3* ASO to h*APOC3* Tg mice, we recorded significant reductions in AAA incidence, maximal aortic diameter, elastin degradation, and dissection, comparable to the control mice (Fig 5G-L). qRT-PCR and ELISA analysis showed no

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

significant changes in the levels of mouse *Apoc3* and human *APOC3* (Fig 5M-P). There were no significant changes in the TG and TC metabolism-related genes in the liver, such as *Apoc2*, *Apoa5*, *Apoe*, *Apob*, *Mttp*, *Fasn*, *Srebp1c*, *Ldlr*, and *Pcsk9* (Supplementary Fig 8). *Angptl3* ASO administration did not significantly change body weight or systolic blood pressure (Fig 5Q-R). Overall, our findings demonstrate that administration of *Angptl3* ASO protected against hypertriglyceridemia accelerated AAA development in h*APOC3* Tg mice.

Angptl3 ASO inhibits AAA development in _Apoe_-deficient mice.

ApoE-deficient mice have high levels of VLDL due to impaired clearance of chylomicron and VLDL. Compared with age and sex-matched C57BL/6J mice, *Apoe*-deficient mice show significantly increased plasma levels of TC and moderately increased TG levels when fed a standard rodent diet.[35] Similar to the observation in h*APOC3* Tg mice, administration of *Angptl3* ASO dramatically reduced hepatic *Angptl3* mRNA expression and the circulating levels of ANGPTL3 (Fig 6A-C). As expected, administration of the *Angptl3* ASO significantly decreased TG concentrations by 50%, NEFA by 31%, and slightly decreased TC concentrations by 8% in *Apoe*-deficient mice fed a standard rodent laboratory diet (Fig 6D-F). We also used size exclusion chromatography to separate lipoprotein classes and found decreased TG concentrations, mainly in VLDL and IDL (Fig 6I), while cholesterol concentrations were slightly reduced in VLDL and HDL (Fig 6J). Blood pressure measurements and body weight recordings revealed no significant difference between control ASO and *Angptl3* ASO-administered mice (Fig 6G, H). Consistent with the literature, AAA incidence in *Apoe*-deficient mice was 83% in the control group (Fig 6K, N). *Angptl3* ASO administration largely inhibited AAA development, as evidenced by significantly decreased AAA incidence and maximal aortic diameters (Fig 6N, O). Depletion of hepatic *Angptl3* had limited effects on the expression of genes involved in lipogenesis and cholesterol metabolism (Fig 6P). Taken together, these data demonstrated that lowering TG and NEFA concentrations by *Angptl3* ASO inhibited AAA development in *Apoe*-deficient mice.

Discussion

AAA screening programs have identified many asymptomatic AAA and effectively reduced aneurysm-related mortality. Thus, limiting aneurysm growth and reducing the risk of aneurysm rupture has become a key priority for the treatment of AAA.[36] Based on the genetic, proteomic, and metabolomic findings, we identify that increased TG concentrations accelerate AAA formation and rupture using three hypertriglyceridemia murine models. Of clinical relevance, we provide evidence that lowering TG and NEFA

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

concentrations by *Angptl3* ASO administration dramatically inhibited AAA development and rupture.

Mendelian Randomization (MR) using protein quantitative trait loci (pQTLs) as instrumental variables (IVs) can help infer causality and identify drug targets for complex diseases. By integrating pQTLs from ten large GWAS on circulating proteins, we updated the 'actionable' druggable target pool into an enlarged set of 2,698 proteins. Genetically determined APOA5 and LPL, two critical molecules regulating triglyceride metabolism, were negatively associated with AAA risk. In contrast, the variants related to APOC3 with increased TG concentrations were associated with increased AAA risk, underscoring the role of triglyceride metabolism in human AAA development, consistent with other genetic findings.[7,8] We further explored the causal effects of metabolites on AAA risk using IVs from 233 NMR-measured circulating metabolites.[20] The strong associations found in VLDL and its subfractions as well as free fatty acid concentrations, further highlighted the importance of TG metabolism in AAA. Collectively, these findings emphasize the significance of TG in AAA risk and provide potential candidates for AAA prevention and treatment.

According to the literature and our experience, young C57BL/6J mice, when fed a standard rodent laboratory diet, have low AAA incidence when infused with AngII.[26,37] Hyperlipidemia increases the AAA incidence during AngII infusion in *Ldlr* and *Apoe*-deficient mice or C57BL/6J mice with an AAV expressing a gain-of-function mutant of PCSK9, in which *Ldlr*-deficient mice and PCSK9 overexpressing mice are fed a Western diet to augment hypercholesterolemia.[26] Compared with C57BL/6J mice, *Ldlr* or *Apoe*-deficient mice have significantly increased TC and TG concentrations, which mainly distribute in VLDL fractions using size exclusion chromatography to separate lipoprotein classes,[38] indicating that increased concentrations of large, TG-rich lipoproteins are associated with AAA formation. Our previous study demonstrated that AAA development is accelerated with modestly hypercholesterolemic conditions, but further elevation of cholesterol above a threshold level does not enhance AAA progression.[37] Here, we present that increased TG concentrations contribute to AAA development, dissection, and rupture in a TG-concentration-dependent manner using three hypertriglyceridemia mouse models. The moderately increased TG concentrations in *Apoa5* deficiency mice accelerated AAA development, dramatically increased TG concentrations in h*APOC3* transgenic mice caused AAA dissection, and severely high TG concentrations resulted in aortic rupture and death in inducible *Lpl*-deficient mice. We also evaluated the effects of increased TG concentrations on aneurysm growth in the elastase-induced AAA model. Previous studies have demonstrated that the aneurysm growth in the PPE model is independent of hypercholesterolemic conditions using C57BL/6J mice with

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

PCSK9 overexpression or *Apoe*-deficient mice.[27,39] Using the PPE-induced AAA model, we demonstrated that increased TG concentrations aggravated AAA growth in both male and female *APOC3* Tg mice. Furthermore, clinical observation shows that plasma TG concentrations are higher in AAA patients than in controls.[9] In a prospective epidemiological study (the British United Provident Association [BUPA] study), the risk of death from AAA rupture is strongly related to serum TG concentrations.[10] Together, these findings pave the way for future studies of the role of triglyceride and related metabolites in AAA development.

Importantly, our study demonstrates that lowering TG and NEFA levels by administrating *Angptl3* ASO inhibits AAA development in both h*APOC3* transgenic mice and *Apoe*-deficient mice. ApoC-III raises TG concentrations by inhibiting LPL activity, reducing hepatic uptake of TG-rich lipoproteins, and promoting VLDL secretion. ApoE acts as a critical ligand for the LDL receptor and the LDL receptor-related protein, facilitating the uptake of chylomicron and VLDL remnants into hepatocytes. Deficiency of ApoE causes elevated TG and TC levels. In both *APOC3* transgenic mice and *Apoe*-deficient mice, triglycerides and cholesterol are mainly distributed in VLDL fractions. Administration of *Angptl3* ASO dramatically reduced TG levels in VLDL and IDL fractions, consistent with decreased TG concentrations in plasma, supporting the hypothesis that large-sized TG-rich lipoproteins and related metabolites contribute to AAA progression and rupture. These findings also provide evidence that lowering TG-rich lipoproteins is a potential therapeutic strategy. ANGPTL8 and ANGPTL3 form a complex that markedly inhibits LPL activity. Similar to the effects of *Angptl3* ASO on AAA, *Angplt8*-deficiency or knockdown reduced AAA formation by lowering TG concentrations and suppressing the inflammatory response in *Apoe*-deficient mice.[40] Administration of fenofibrate also reduced the severity of experimental AAA in *Ldlr*- and *Apoe*-deficient mice.[41,42] However, fenofibrate did not significantly limit AAA growth in AAA patients in FAME-2 (Fenofibrate in the Management of Abdominal Aortic Aneurysm 2), a placebo-controlled clinical trial.[43] We should note that it may take an estimated five years for a small AAA with a diameter of 40–55 mm to reach 55 mm, the size threshold for intervention.[36] In the FAME-2 study, AAA diameters in the control group increased only about 1 mm after a 24-week observation period, making it hard to determine the effects of fenofibrate. Additionally, AAA diameters in the two groups began to diverge at the end of the evaluation, suggesting that a long-term clinical trial with a larger sample size is needed to carefully assess the effects of triglyceride-lowering on AAA growth and rupture.

AAA is characterized by pathological remodeling of the aortic ECM, including elastolysis and collagenolysis. LOX is a crucial enzyme involved in the cross-linking of collagen and elastin in the ECM to maintain the structural integrity of the aortic wall. Impairments

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

in LOX activity due to genetic mutations can lead to connective tissue disorders and promote aorta dissection.[44] *Lox*-deficient mice exhibit severe defects in vascular development, leading to perinatal death from aortic aneurysm.[31] β-Aminopropionitrile (BAPN) is a well-known inhibitor of LOX and has been used extensively in research to accelerate AAA formation and rupture.[45] LOX is initially synthesized as a preproprotein and secreted into the extracellular space, where the prolysyl oxidase is cleaved by proteases, including BMP-1, ADAMTS-2, and ADAMTS-14. Increased TG concentrations or the presence of palmitate dramatically blocked LOX maturation in aortas and HASMCs. Based on RNA-seq findings, BMP-1 and ADAMTS-2 are highly abundant in HASMC. PA downregulated the expression of BMP-1 and ADAMTS-2, causing decreased LOX maturation. Additionally, PA induces vascular SMC apoptosis, promotes inflammatory responses, enhances oxidative stress, and triggers proliferation and migration, contributing to the progression of vascular diseases such as atherosclerosis and hypertension.[46] In this study, we demonstrated that PA, potentially originating from plasma triglycerides, may contribute to AAA development by inhibiting LOX maturation. Lowering TG and NEFA by administration of *Angptl3* ASO can inhibit AAA development, suggesting that managing triglyceride concentrations and related metabolites through lifestyle changes and pharmacotherapy may reduce the risk of AAA development.

Plasma TG concentrations include the content of various lipoprotein particles. Multiple genes, such as LPL, APOC3, APOC2, APOA5, and ANGPTL3, influence TG metabolism and regulate plasma TG concentrations. Among them, APOC3 and ANGPTL3 are targets for drug development because loss-of-function mutations in APOC3 and ANGPTL3 are associated with improved lipid profiles and reduced cardiovascular risk. Preclinical and clinical data have well documented that ApoC-III or ANGPTL3 inhibitors effectively reduce severe hypertriglyceridemia. These inhibitors include antisense nucleotides (ASO),[14,16,34] monoclonal antibodies (mAb),[47] small interfering RNA (siRNA),[48,49], and CRISPR-cas gene editing strategies.[50,51] Preclinical and clinical data have demonstrated that ANGPTL3 inhibitors are highly effective for treating severe hypertriglyceridemia by upregulating LPL activity and facilitating the hydrolysis and clearance of TG-rich lipoproteins. As h*APOC3* transgenic mice have very high APOC3 and TG concentrations, *Angptl3* ASO was administrated at 50 mg/kg/week in previous studies.[16] In this study, administration of an *Angptl3* ASO at a much lower dosage effectively reduced AAA development in h*APOC3* transgenic mice and *Apoe*-deficient mice through reducing TG concentrations, especially TG concentrations in VLDL fractions. We observed that the administration of *Angptl3* ASO mainly decreased plasma TG concentrations with a limited reduction in plasma TC concentrations, further

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

supporting the idea that managing TG-rich lipoprotein concentrations is a potential therapeutic strategy for treating AAA.

In summary, the present studies, combined with recent genetic, proteomic, and metabolomic findings, indicate that increased TG concentrations increase AAA risk. Individuals at higher genetic risk for AAA might benefit from targeted interventions. Understanding the association between triglyceride concentrations and AAA risk has important clinical implications. These findings prove that ASO administration targeting ANGPTL3 may become a therapy to reduce the risk of AAA. The present studies should stimulate further experimental and clinical investigations of the mechanisms and therapeutic strategies for AAA treatment via triglyceride-lowering therapies.

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Funding

This study was partially supported by the National Institutes of Health grants HL166203 (Y.G.), HL165688 (Y.G. and A.S.), HL109946 and HL134569 (Y.E.C.), HL151524 (L.C.), HL153710 and HL138139 (J.Z.), HL172832 (G. Zhao), R35HL155649 (A.D.), UL1TR001998 (A.D.), R21 NS11191 (A.S.) and the American Heart Association Merit award 23MERIT1036341 (A.D.).

Disclosures

The authors have no competing interests.

Data availability

All genetic data used in this study were obtained from publicly available consortiums. The RNAseq original data generated during this study will be deposited in a publicly accessible database upon acceptance of the manuscript.

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

References

1. Nordon, I.M., Hinchliffe, R.J., Loftus, I.M. & Thompson, M.M. Pathophysiology and epidemiology of abdominal aortic aneurysms. *Nat Rev Cardiol* **8**, 92-102 (2011).
2. United Kingdom Small Aneurysm Trial, P.*, et al.* Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. *N Engl J Med* **346**, 1445-1452 (2002).
3. Soden, P.A.*, et al.* Outcomes for symptomatic abdominal aortic aneurysms in the American College of Surgeons National Surgical Quality Improvement Program. *J Vasc Surg* **64**, 297-305 (2016).
4. Reimerink, J.J., van der Laan, M.J., Koelemay, M.J., Balm, R. & Legemate, D.A. Systematic review and meta-analysis of population-based mortality from ruptured abdominal aortic aneurysm. *Br J Surg* **100**, 1405-1413 (2013).
5. Golledge, J., Thanigaimani, S., Powell, J.T. & Tsao, P.S. Pathogenesis and management of abdominal aortic aneurysm. *Eur Heart J* **44**, 2682-2697 (2023).
6. Roychowdhury, T.*, et al.* Genome-wide association meta-analysis identifies risk loci for abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target. *Nat Genet* **55**, 1831-1842 (2023).
7. Harrison, S.C.*, et al.* Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis. *JAMA Cardiol* **3**, 26-33 (2018).
8. Klarin, D.*, et al.* Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. *Nat Genet* **50**, 1514-1523 (2018).
9. Norrgard, O., Angquist, K.A. & Johnson, O. Familial aortic aneurysms: serum concentrations of triglyceride, cholesterol, HDL-cholesterol and (VLDL + LDL)-cholesterol. *Br J Surg* **72**, 113-116 (1985).
10. Watt, H.C.*, et al.* Serum triglyceride: a possible risk factor for ruptured abdominal aortic aneurysm. *Int J Epidemiol* **27**, 949-952 (1998).
11. Subramanian, S. Hypertriglyceridemia: Pathophysiology, Role of Genetics, Consequences, and Treatment. in *Endotext* (eds. Feingold, K.R.*, et al.*) (South Dartmouth (MA), 2000).
12. Pennacchio, L.A.*, et al.* An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. *Science* **294**, 169-173 (2001).
13. Breckenridge, W.C., Little, J.A., Steiner, G., Chow, A. & Poapst, M. Hypertriglyceridemia associated with deficiency of apolipoprotein C-II. *N Engl J Med* **298**, 1265-1273 (1978).
14. Witztum, J.L.*, et al.* Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. *N Engl J Med* **381**, 531-542 (2019).

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

15. Bergmark, B.A., *et al.* Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. *N Engl J Med* **390**, 1770-1780 (2024).
16. Graham, M.J., *et al.* Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. *N Engl J Med* **377**, 222-232 (2017).
17. Rosenson, R.S., *et al.* Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. *N Engl J Med* (2024).
18. Burgess, S., *et al.* Using genetic association data to guide drug discovery and development: Review of methods and applications. *Am J Hum Genet* **110**, 195-214 (2023).
19. Gaziano, L., *et al.* Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19. *Nat Med* **27**, 668-676 (2021).
20. Karjalainen, M.K., *et al.* Genome-wide characterization of circulating metabolic biomarkers. *Nature* **628**, 130-138 (2024).
21. Ibrahim, M., Thanigaimani, S., Singh, T.P., Morris, D. & Golledge, J. Systematic review and Meta-Analysis of Mendelian randomisation analyses of Abdominal aortic aneurysms. *Int J Cardiol Heart Vasc* **35**, 100836 (2021).
22. Raffort, J., *et al.* Diabetes and aortic aneurysm: current state of the art. *Cardiovasc Res* **114**, 1702-1713 (2018).
23. Daugherty, A. & Cassis, L. Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -/- mice. *Ann N Y Acad Sci* **892**, 108-118 (1999).
24. Daugherty, A., Manning, M.W. & Cassis, L.A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. *J Clin Invest* **105**, 1605-1612 (2000).
25. Lu, H., *et al.* Hypercholesterolemia Induced by a PCSK9 Gain-of-Function Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in C57BL/6 Mice-Brief Report. *Arterioscler Thromb Vasc Biol* **36**, 1753-1757 (2016).
26. Sawada, H., Lu, H.S., Cassis, L.A. & Daugherty, A. Twenty Years of Studying AngII (Angiotensin II)-Induced Abdominal Aortic Pathologies in Mice: Continuing Questions and Challenges to Provide Insight Into the Human Disease. *Arterioscler Thromb Vasc Biol* **42**, 277-288 (2022).
27. Mulorz, J., *et al.* Hyperlipidemia does not affect development of elastase-induced abdominal aortic aneurysm in mice. *Atherosclerosis* **311**, 73-83 (2020).
28. Golledge, J. Abdominal aortic aneurysm: update on pathogenesis and medical treatments. *Nat Rev Cardiol* **16**, 225-242 (2019).
29. Carta, G., Murru, E., Banni, S. & Manca, C. Palmitic Acid: Physiological Role, Metabolism and Nutritional Implications. *Front Physiol* **8**, 902 (2017).
30. Staiculescu, M.C., Kim, J., Mecham, R.P. & Wagenseil, J.E. Mechanical behavior and matrisome gene expression in the aneurysm-prone thoracic aorta of

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

newborn lysyl oxidase knockout mice. *Am J Physiol Heart Circ Physiol* **313**, H446-H456 (2017).

31. Lee, V.S.*, et al.* Loss of function mutation in LOX causes thoracic aortic aneurysm and dissection in humans. *Proc Natl Acad Sci U S A* **113**, 8759-8764 (2016).
32. Franklin, M.K.*, et al.* beta-Aminopropionitrile Induces Distinct Pathologies in the Ascending and Descending Thoracic Aortic Regions of Mice. *Arterioscler Thromb Vasc Biol* **44**, 1555-1569 (2024).
33. Eguchi, K.*, et al.* Saturated fatty acid and TLR signaling link beta cell dysfunction and islet inflammation. *Cell Metab* **15**, 518-533 (2012).
34. Bergmark, B.A.*, et al.* Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70. *Circulation* **145**, 1377-1386 (2022).
35. Plump, A.S.*, et al.* Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. *Cell* **71**, 343-353 (1992).
36. Ulug, P., Powell, J.T., Martinez, M.A., Ballard, D.J. & Filardo, G. Surgery for small asymptomatic abdominal aortic aneurysms. *Cochrane Database Syst Rev* **7**, CD001835 (2020).
37. Liu, J.*, et al.* Associations of ApoAI and ApoB-containing lipoproteins with AngII-induced abdominal aortic aneurysms in mice. *Arterioscler Thromb Vasc Biol* **35**, 1826-1834 (2015).
38. Ishibashi, S., Herz, J., Maeda, N., Goldstein, J.L. & Brown, M.S. The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. *Proc Natl Acad Sci U S A* **91**, 4431-4435 (1994).
39. Ikezoe, T.*, et al.* No Effect of Hypercholesterolemia on Elastase-Induced Experimental Abdominal Aortic Aneurysm Progression. *Biomolecules* **11**(2021).
40. Yu, H.*, et al.* ANGPTL8 deletion attenuates abdominal aortic aneurysm formation in ApoE-/- mice. *Clin Sci (Lond)* **137**, 979-993 (2023).
41. Krishna, S.M.*, et al.* Fenofibrate increases high-density lipoprotein and sphingosine 1 phosphate concentrations limiting abdominal aortic aneurysm progression in a mouse model. *Am J Pathol* **181**, 706-718 (2012).
42. Golledge, J.*, et al.* Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm. *Atherosclerosis* **210**, 51-56 (2010).
43. Pinchbeck, J.L.*, et al.* Randomized Placebo-Controlled Trial Assessing the Effect of 24-Week Fenofibrate Therapy on Circulating Markers of Abdominal Aortic

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Aneurysm: Outcomes From the FAME -2 Trial. *J Am Heart Assoc* **7**, e009866 (2018).

44. Guo, D.C.*, et al.* LOX Mutations Predispose to Thoracic Aortic Aneurysms and Dissections. *Circ Res* **118**, 928-934 (2016).
45. Kanematsu, Y.*, et al.* Pharmacologically induced thoracic and abdominal aortic aneurysms in mice. *Hypertension* **55**, 1267-1274 (2010).
46. Hu, Y., Fan, Y., Zhang, C. & Wang, C. Palmitic acid inhibits vascular smooth muscle cell switch to synthetic phenotype via upregulation of miR-22 expression. *Aging (Albany NY)* **14**, 8046-8060 (2022).
47. Gaudet, D.*, et al.* Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. *Eur Heart J* **45**, 2422-2434 (2024).
48. Watts, G.F.*, et al.* RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts. *Nat Med* **29**, 2216-2223 (2023).
49. Gaudet, D.*, et al.* RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia. *NEJM Evid* **2**, EVIDoa2200325 (2023).
50. Zha, Y.*, et al.* CRISPR/Cas9-mediated knockout of APOC3 stabilizes plasma lipids and inhibits atherosclerosis in rabbits. *Lipids Health Dis* **20**, 180 (2021).
51. Zuo, Y.*, et al.* Liver-specific in vivo base editing of Angptl3 via AAV delivery efficiently lowers blood lipid levels in mice. *Cell Biosci* **13**, 109 (2023).

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figures

Fig. 1: Mendelian Randomization identifies circulating proteins and metabolites causally related to AAA risk.

A, Outline of the analyses performed. Two-sample Mendelian Randomization (MR) analyses were applied to determine the causal effects of circulating proteins, and nuclear magnetic resonance (NMR) measured circulating metabolites on the risk of abdominal aortic aneurysm (AAA) using multiple data sources. **B**, Forest plot displaying the causal effects of 41 proteins identified through MR-Wald ratio analysis after Bonferroni correction. **C**, Classifications of NMR metabolites and the relative lipid compositions of the 14 lipoprotein subclasses (left). All 14 lipoprotein subclass particles are illustrated using the same size scale, with diameters based on mean values from 5,651 participants in the Northern Finland Birth Cohort 1966 (NFBC66). Note that the size of the LDL and HDL particles in the figure is multiplied by 1.5 and 2.0, respectively. The right side features a circular histplot of the MR results for 141 metabolites. Each bar's height represents the absolute effect size, while the color indicates the direction and P-value as determined by the MR inverse-variance weighted (IVW) method.

Fig. 2: Impaired LPL activity accelerates AAA development and aortic rupture.

A, Design of the AAA study in *Lpl*-deficient mice. Inducible global *Lpl*-deficient mice were generated by crossing *Lpl* floxed ($Lpl^{f/f}$) mice with β-actin driven tamoxifen-inducible MerCreMer transgenic mice. Low cholesterol, Western diet feeding was initiated 2 weeks after the start of tamoxifen treatment. **B**, Aortic rupture incidence curve during 4 weeks of AngII infusion. **C**, Aortic aneurysm incidence in $Lpl^{f/f}$ (n=11) and i$Lpl^{-/-}$ (n=10) mice. **D**, Design of the AAA study in *Apoa5*-deficient mice. Mice were fed a standard rodent laboratory diet. After 4-week of AngII infusion, aortas from surviving mice were harvested. **E**, Representative aorta of male WT (n = 14) and *Apoa5*-deficient (n = 15) mice after 4 weeks of AngII infusion. Plasma samples were collected on day 28 and subjected individually to analytical chemistry to measure triglycerides (TG) and total cholesterol (TC). **F-J**, The TG (**F**), TC (**G**), maximal aortic diameter (**H**), AAA incidence (**I**), and systolic blood pressure (**J**) in male mice. **K-O**, TG (**K**), TC (**L**), maximal aortic diameter (**M**), AAA incidence (**N**), and systolic blood pressure (**O**) in female WT (n = 10) and *Apoa5*-deficient (n = 8) mice in AngII-induced AAA study. Data are presented as circles and Mean ± SEM (**F-H**, **J -M**, **O**). Statistical analyses were conducted as follows: Chi-Squared test for **C**, **I**, **N**; Mann-Whitney U test for **F**, **M**; Student's t-test for **G**, **H**, **K**, **L**; Kruskal-Wallis test followed by Dunn's post hoc analysis for **J**; One-way ANOVA followed by Sidak post hoc analysis for **O**. SBP, systolic blood pressure.

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Fig. 3: Dramatically increased TG concentrations accelerate AAA development and rupture in h*APOC3* Tg mice.

A, Design of the AAA study in human *APOC3* transgenic (h*APOC3* Tg) mice. Twelve- to 16-week-old h*APOC3* Tg mice (n of male = 15; n of female = 24) or WT littermates (n of male = 17, n of female =21) were infused with AngII (1,000 ng/kg/min) for 4 weeks to induce AAA. Systolic blood pressures were measured before and after AngII infusion. The mice were fed a standard rodent laboratory diet. After 4 weeks, aortas from surviving mice were harvested. Plasma samples were collected on day 28 and subjected individually to analytical chemistry. **B**-**D**, plasma triglycerides (TG) (**B**), total cholesterol (TC) (**C**), and non-esterified fatty acids (**D**) in male mice. Representative aortas of male WT and h*APOC3* Tg mice after 4 weeks of AngII infusion (**E**). Maximal aortic diameter (**F**), AAA incidence (**G**), dissection rate (**H**), and systolic blood pressure (**I**) in male mice. **J**-**Q**, The TG (**J**), TC (**K**), non-esterified fatty acids (**L**), maximal aortic diameter (**M**), AAA incidence (**N**), and dissection rate (**O**) in female WT and h*APOC3* Tg mice after 4 weeks of AngII infusion. Data are presented as circles and Mean ± SEM (**B**-**D**, **F**, **I**-**M**). Statistical analyses were conducted as follows: Mann-Whitney U test for **B**, **D**, **F**, **J**, **K**; Student's t-test for **C**, **L**, **M**; Chi-Squared test for **G**, **H**, **N**, **O**; One-way ANOVA followed by Sidak post hoc analysis for **I**. Scale bars: 1 mm in **E**. SBP, systolic blood pressure; NEFA, non-esterified fatty acids.

Fig. 4: Palmitic acid inhibits LOX maturation in HASMCs and aortas.

A-**F**, Human aortic smooth muscle cells (HASMCs) were starved in OptiMEM-reduced serum medium for 24 hours, followed by incubation with palmitic acid (250 μM; PA) or vehicle (BSA) for another 24 hours. Total RNA was extracted for RNA sequencing or qRT-PCR. **A,** Reactome pathway enrichment analysis of down-regulated genes in the PA group. **B**, Top 5 downregulated Reactome pathways identified from Gene Set Enrichment Analysis (GSEA). **C**, Heatmap of gene expression levels in the collagen chain trimerization pathway. **D**, Heatmap of gene expression levels involved in elastic fiber formation and maturation. qRT-PCR analysis of *LOX* (**E**) and *BMP1*, *ADAMTS2*, and *ADAMTS14* (**F**) (data from 4 independent experiments). **G, I**, HASMCs were starved in OptiMEM for 24 hours, then incubated with PA (250 μM) or vehicle along with TGF-β (10 ng/ml) or vehicle for another 24 hours. Total proteins were extracted for Western blot analysis. **G**, Representative Western blot image of mature LOX and premature form of LOX. **I**, Quantification analysis of mature LOX protein abundance (data from 5 independent experiments). **H**, HASMCs were transfected with adenovirus LacZ or LOX (30 MOI) for 2 hours in a growth medium, then starved in OptiMEM for another 22 hours. Cells were incubated with PA (250 μM) or vehicle for an additional 24

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

hours. Total proteins were then extracted for Western blot analysis of mature and premature LOX. **J**, Eight-week-old male C57BL/6J mice were given saline, vehicle, or ethyl palmitate (600 mg/kg) for 5 consecutive days via intraperitoneal injection. On day 6, mice were euthanized, suprarenal abdominal aortas were isolated, and total protein was extracted and analyzed by Western blot to detect mature LOX abundance in suprarenal abdominal aortas, with corresponding quantifications (n = 5/group). **K**, Twelve- to 16-week-old h*APOC3* Tg mice and littermate control mice were infused with saline or AngII (1,000 ng/kg/min) for 7 days. On day 8, mice were euthanized, suprarenal abdominal aortas were isolated, and total protein was extracted and analyzed by Western blot to detect mature LOX expression in suprarenal abdominal aortas, with corresponding quantifications (n = 3 or 4/genotyping/treatment). Data are presented as dots and Mean ± SEM (**E**, **F**, **I-K**). Statistical analyses were conducted as follows: Student's t-test for **E**, **F**; Mann-Whitney U test followed by Bonferroni correction for **I;** One-way ANOVA followed by Sidak post hoc analysis for **J, K**.

Fig. 5: Administration of *Angptl3* ASO prevents AAA formation in h*APOC3* Tg mice.

A, Design of the *Angptl3* ASO study in human *APOC3* Tg mice. Twelve- to 16-week-old male h*APOC3* Tg mice were given one injection of *Angptl3* ASO (10 mg/kg) or scrambled ASO by subcutaneous administration. After 3 days, mice were infused with AngII (1,000 ng/kg/min) for 25 days. Three more injections (3 mg/kg) were conducted on days 7, 14, and 21. A wild-type group was included, receiving injections of scramble ASO. At the end of the study, aortas, livers, and plasma were harvested. **B**, Relative abundance of *Angptl3* mRNA in livers of the three groups. **C-D**, Plasma ANGPTL3 protein concentrations (**C**) and non-esterified fatty acids (**D**) at the endpoint. **E** to **F**, Plasma triglycerides (TG) (**E**) and total cholesterol (TC) (**F**) concentrations on days 0, 3, and 28. **G**, Representative aortic trees from the 3 groups. **H**, Representative H&E staining (left) and Verhoeff-Van Gieson (VVG) staining (right) of suprarenal abdominal aorta sections. **I-L**, Quantifications of AAA incidence (**I**), maximal aorta diameter (**J**), elastic fiber degradation score (**K**), and dissection rate (**L**) among the 3 groups. **M**, Relative abundance of *Apoc3* in the liver. **N**, Plasma mouse-specific APOC3 concentrations were measured by ELISA at the endpoint. **O**, Relative liver abundance of human *APOC3*. **P**, Plasma human APOC3 concentrations were determined by ELISA at the endpoint. **Q**, Body weight comparisons among the 3 groups before and at the end of the study. **R**, Systolic blood pressure comparisons among the 3 groups before and at the end of the study. Data are presented as circles/dots and Mean ± SEM or Mean only. Statistical analyses were conducted as follows: One-way ANOVA followed by Sidak post

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

hoc analysis for **B**, **C**, **D**, **E,** day 3 of **F, M, N, R**; Kruskal-Wallis test followed by Dunn's post hoc analysis for day 0 and 28 of **F, J**, **K**, **O**, **P, Q**; Chi-Squared test for **I**, **L**. Scale bars: 1 mm in **G**, 50 μm in **H**. SBP, systolic blood pressure; NEFA, non-esterified fatty acids; #, $P < 0.005$ of the comparison of Ctr and WT group. *, $P < 0.005$ of the comparison of Ctr and ASO group.

Fig. 6: Administration of *Angptl3* ASO prevents AAA formation in *Apoe*-deficient mice.

A, Design of the *Angptl3* ASO study in male *Apoe*-deficient mice. Ten-week-old male *Apoe*-deficient mice were given a subcutaneous injection of *Angptl3* ASO (10 mg/kg; n = 13) or scrambled ASO (n = 12). After 3 days, mice were infused with AngII (1,000 ng/kg/min) for 25 days. Three more injections were administered on days 7, 14, and 21. At the end of the study, aortas, livers, and plasma were harvested. **B**, Relative abundance of *Angptl3* mRNA in the liver. **C-D**, Plasma ANGPTL3 protein concentrations (**C**), and non-esterified fatty acids (**D**) at the endpoint. **E,** Plasma triglycerides (TG) levels on days 0, 3, and 28. **F**, Plasma total cholesterol (TC) concentrations on days 3 and 28. **G**, Systolic blood pressure before and after AngII infusion. **H**, Body weight changes. TG (**I**) and cholesterol (**J**) concentrations of size exclusion chromatography fractionated plasma from animals (n = 4 in the control group, n = 4 in the *Angptl3* ASO group) determined by enzymatic assays. Fractions 8 to 11 contained VLDL, fractions 12 to 17 contained IDL and LDL, and fractions 22 to 25 contained HDL. **K**, Representative aortic images from the 2 groups. **N-O**, Quantification of AAA incidence (**N**) and maximal aortic diameter (**O**). **P**, Relative liver mRNA abundance of genes related to VLDL production (*Apob, Mttp, Srebp1c, Scd, Fasn*), TG lipolysis (*Apoc2, Apoc3, Apoa5, Lpl*), and TC regulation (*Pcsk9, Ldlr, Lrp1*). Data are presented as circles/dots and/or Mean ± SEM. Statistical analyses were conducted as follows: Student's t-test for **B**, **C**, day 0 and 28 of **E**, day 28 of **F**; Mann-Whitney U test for **D**, day 3 of **E** and **F**, **O**; One-way ANOVA followed by Sidak post hoc analysis for **G**; Chi-Squared test for **N;** Student's t-test or Mann-Whitney U test for **P**. Scale bars: 1 mm in **K**. SBP, systolic blood pressure; NEFA, non-esterified fatty acids.

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure 1



medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure 4



medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure 5



medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311621; this version posted August 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure 6